AAAAAA

   
Results: 1-25 | 26-50 | 51-57
Results: 1-25/57
RELAPSE AFTER SUCCESSFUL TREATMENT WITH IMMUNOTHERAPY - LESSONS FOR THE FUTURE
Authors: FISHER RI
Citation: Ri. Fisher, RELAPSE AFTER SUCCESSFUL TREATMENT WITH IMMUNOTHERAPY - LESSONS FOR THE FUTURE, The cancer journal from Scientific American, 4(2), 1998, pp. 78-79
NEW REAL CLINICAL ENTITIES
Authors: FISHER RI MILLER TP GROGAN TM
Citation: Ri. Fisher et al., NEW REAL CLINICAL ENTITIES, The cancer journal from Scientific American, 4, 1998, pp. 5-12
CLINICOPATHOLOGICAL CORRELATES OF THE REAL CLASSIFICATION
Authors: FISHER RI
Citation: Ri. Fisher, CLINICOPATHOLOGICAL CORRELATES OF THE REAL CLASSIFICATION, Leukemia & lymphoma (Print), 30, 1998, pp. 17-18
INTRODUCTION - NON-HODGKINS-LYMPHOMA - APPROACHES TO CURRENT THERAPY
Authors: FISHER RI
Citation: Ri. Fisher, INTRODUCTION - NON-HODGKINS-LYMPHOMA - APPROACHES TO CURRENT THERAPY, Oncology, 12(10), 1998, pp. 9-10
CHOP THERAPY - HAS SHORTER-COURSE THERAPY HAD AN IMPACT ON LYMPHOMAS
Authors: GAYNOR ER FISHER RI
Citation: Er. Gaynor et Ri. Fisher, CHOP THERAPY - HAS SHORTER-COURSE THERAPY HAD AN IMPACT ON LYMPHOMAS, Cancer investigation, 16(1), 1998, pp. 26-32
METAANALYSIS OF CHEMOTHERAPY VERSUS COMBINED-MODALITY TREATMENT TRIALS IN HODGKINS-DISEASE
Authors: LOEFFLER M BROSTEANU O HASENCLEVER D SEXTRO M ASSOULINE D BARTOLUCCI AA CASSILETH PA CROWTHER D DIEHL V FISHER RI HOPPE RT JACOBS P PATER JL PAVLOVSKY S THOMPSON E WIERNIK P
Citation: M. Loeffler et al., METAANALYSIS OF CHEMOTHERAPY VERSUS COMBINED-MODALITY TREATMENT TRIALS IN HODGKINS-DISEASE, Journal of clinical oncology, 16(3), 1998, pp. 818-829
PHASE-II TRIAL OF PACLITAXEL BY 24-HOUR CONTINUOUS-INFUSION FOR RELAPSED NON-HODGKINS-LYMPHOMAS - SOUTHWEST-ONCOLOGY-GROUP TRIAL-9246
Authors: PRESS OW LEBLANC M OROURKE TJ GAGNET S CHAPMAN RA BALCERZAK SP FISHER RI
Citation: Ow. Press et al., PHASE-II TRIAL OF PACLITAXEL BY 24-HOUR CONTINUOUS-INFUSION FOR RELAPSED NON-HODGKINS-LYMPHOMAS - SOUTHWEST-ONCOLOGY-GROUP TRIAL-9246, Journal of clinical oncology, 16(2), 1998, pp. 574-578
MOPP ABV HYBRID CHEMOTHERAPY FOR ADVANCED HODGKINS-DISEASE SIGNIFICANTLY IMPROVES FAILURE-FREE AND OVERALL SURVIVAL - THE 8-YEAR RESULTS OFTHE INTERGROUP TRIAL/
Authors: GLICK JH YOUNG ML HARRINGTON D SCHILSKY RL BECK T NEIMAN R FISHER RI PETERSON BA OKEN MM
Citation: Jh. Glick et al., MOPP ABV HYBRID CHEMOTHERAPY FOR ADVANCED HODGKINS-DISEASE SIGNIFICANTLY IMPROVES FAILURE-FREE AND OVERALL SURVIVAL - THE 8-YEAR RESULTS OFTHE INTERGROUP TRIAL/, Journal of clinical oncology, 16(1), 1998, pp. 19-26
AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE AGGRESSIVE NON-HODGKINS-LYMPHOMA - VALUE OF AUGMENTED PREPARATIVE REGIMENS - A SOUTHWEST-ONCOLOGY-GROUP TRIAL
Authors: STIFF PJ DAHLBERG S FORMAN SJ MCCALL AR HORNING SJ NADEMANEE AP BLUME KG LEBLANC M FISHER RI
Citation: Pj. Stiff et al., AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE AGGRESSIVE NON-HODGKINS-LYMPHOMA - VALUE OF AUGMENTED PREPARATIVE REGIMENS - A SOUTHWEST-ONCOLOGY-GROUP TRIAL, Journal of clinical oncology, 16(1), 1998, pp. 48-55
TREATMENT OF INTERMEDIATE-GRADE AND HIGH-GRADE NON-HODGKINS-LYMPHOMA - REPLY
Authors: MILLER TP LEBLANC M FISHER RI
Citation: Tp. Miller et al., TREATMENT OF INTERMEDIATE-GRADE AND HIGH-GRADE NON-HODGKINS-LYMPHOMA - REPLY, The New England journal of medicine, 339(20), 1998, pp. 1477-1477
CHEMOTHERAPY ALONE COMPARED WITH CHEMOTHERAPY PLUS RADIOTHERAPY FOR LOCALIZED INTERMEDIATE-AND HIGH-GRADE NON-HODGKINS-LYMPHOMA
Authors: MILLER TP DAHLBERG S CASSADY JR ADELSTEIN DJ SPIER CM GROGAN TM LEBLANC M CARLIN S CHASE E FISHER RI
Citation: Tp. Miller et al., CHEMOTHERAPY ALONE COMPARED WITH CHEMOTHERAPY PLUS RADIOTHERAPY FOR LOCALIZED INTERMEDIATE-AND HIGH-GRADE NON-HODGKINS-LYMPHOMA, The New England journal of medicine, 339(1), 1998, pp. 21-26
BCL-2 EXPRESSION CORRELATES WITH LOWER PROLIFERATIVE ACTIVITY IN THE INTERMEDIATE-GRADE AND HIGH-GRADE NON-HODGKINS-LYMPHOMAS - AN EASTERN CCOOPERATIVE ONCOLOGY GROUP AND SOUTHWEST-ONCOLOGY-GROUP COOPERATIVE LABORATORY STUDY
Authors: WINTER JN ANDERSEN J REED JC KRAJEWSKI S VARIAKOJIS D BAUER KD FISHER RI GORDON LI OKEN MM JIANG SW JEFFRIES D DOMER P
Citation: Jn. Winter et al., BCL-2 EXPRESSION CORRELATES WITH LOWER PROLIFERATIVE ACTIVITY IN THE INTERMEDIATE-GRADE AND HIGH-GRADE NON-HODGKINS-LYMPHOMAS - AN EASTERN CCOOPERATIVE ONCOLOGY GROUP AND SOUTHWEST-ONCOLOGY-GROUP COOPERATIVE LABORATORY STUDY, Blood, 91(4), 1998, pp. 1391-1398
OUTPATIENT SUBCUTANEOUS INTERLEUKIN-2 AND INTERFERON-ALPHA FOR METASTATIC RENAL-CELL CANCER - 5-YEAR FOLLOW-UP OF THE CYTOKINE WORKING GROUP-STUDY
Authors: DUTCHER JP FISHER RI WEISS G ARONSON F MARGOLIN K LOUIE A MIER J CALIENDO G SOSMAN JA ECKARDT JR ERNEST M DOROSHOW J ATKINS M
Citation: Jp. Dutcher et al., OUTPATIENT SUBCUTANEOUS INTERLEUKIN-2 AND INTERFERON-ALPHA FOR METASTATIC RENAL-CELL CANCER - 5-YEAR FOLLOW-UP OF THE CYTOKINE WORKING GROUP-STUDY, The cancer journal from Scientific American, 3(3), 1997, pp. 157-162
HIGH-DOSE ALDESLEUKIN IN RENAL-CELL CARCINOMA - LONG-TERM SURVIVAL UPDATE
Authors: FISHER RI ROSENBERG SA SZNOL M PARKINSON DR FYFE G
Citation: Ri. Fisher et al., HIGH-DOSE ALDESLEUKIN IN RENAL-CELL CARCINOMA - LONG-TERM SURVIVAL UPDATE, The cancer journal from Scientific American, 3, 1997, pp. 70-72
CONCURRENT PHASE-I TRIALS OF INTRAVENOUS INTERLEUKIN-6 IN SOLID TUMORPATIENTS - REVERSIBLE DOSE-LIMITING NEUROLOGICAL TOXICITY
Authors: SOSMAN JA ARONSON FR SZNOL M ATKINS MB DUTCHER JP WEISS GR ISAACS RE MARGOLIN KA FISHER RI ERNEST ML MIER J OLEKSOWICZ L ECKHARDT JR LEVITT D DOROSHOW JH
Citation: Ja. Sosman et al., CONCURRENT PHASE-I TRIALS OF INTRAVENOUS INTERLEUKIN-6 IN SOLID TUMORPATIENTS - REVERSIBLE DOSE-LIMITING NEUROLOGICAL TOXICITY, Clinical cancer research, 3(1), 1997, pp. 39-46
A SOUTHWEST-ONCOLOGY-GROUP PERSPECTIVE ON THE REVISED EUROPEAN-AMERICAN LYMPHOMA CLASSIFICATION
Authors: GROGAN TM MILLER TP FISHER RI
Citation: Tm. Grogan et al., A SOUTHWEST-ONCOLOGY-GROUP PERSPECTIVE ON THE REVISED EUROPEAN-AMERICAN LYMPHOMA CLASSIFICATION, Hematology/oncology clinics of North America, 11(5), 1997, pp. 819
FOLLICULAR LYMPHOMAS - DO HISTOLOGIC SUBTYPES PREDICT OUTCOMES
Authors: MILLER TP LEBLANC M GROGAN TM FISHER RI
Citation: Tp. Miller et al., FOLLICULAR LYMPHOMAS - DO HISTOLOGIC SUBTYPES PREDICT OUTCOMES, Hematology/oncology clinics of North America, 11(5), 1997, pp. 893
CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, AND PREDNISONE VERSUS INTENSIVE CHEMOTHERAPY IN NON-HODGKINS-LYMPHOMA
Authors: FISHER RI
Citation: Ri. Fisher, CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, AND PREDNISONE VERSUS INTENSIVE CHEMOTHERAPY IN NON-HODGKINS-LYMPHOMA, Cancer chemotherapy and pharmacology, 40, 1997, pp. 42-46
MANTLE-CELL LYMPHOMA - CLASSIFICATION AND THERAPEUTIC IMPLICATIONS
Authors: FISHER RI
Citation: Ri. Fisher, MANTLE-CELL LYMPHOMA - CLASSIFICATION AND THERAPEUTIC IMPLICATIONS, Annals of oncology, 7, 1996, pp. 35-39
REPORT OF WORKSHOP-5 - EARLY HIGH-DOSE CHEMOTHERAPY
Authors: FISHER RI
Citation: Ri. Fisher, REPORT OF WORKSHOP-5 - EARLY HIGH-DOSE CHEMOTHERAPY, Annals of oncology, 7, 1996, pp. 131-133
LONG-TERM RESPONSE DATA FOR 255 PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA TREATED WITH HIGH-DOSE RECOMBINANT INTERLEUKIN-2 THERAPY
Authors: FYFE GA FISHER RI ROSENBERG SA SZNOL M PARKINSON DR LOUIE AC
Citation: Ga. Fyfe et al., LONG-TERM RESPONSE DATA FOR 255 PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA TREATED WITH HIGH-DOSE RECOMBINANT INTERLEUKIN-2 THERAPY, Journal of clinical oncology, 14(8), 1996, pp. 2410-2411
LYMPHOMA CLASSIFICATION - THE GAP BETWEEN BIOLOGY AND CLINICAL MANAGEMENT IS CLOSING
Authors: HIDDEMANN W LONGO DL COIFFIER B FISHER RI CABANILLAS F CAVALLI F NADLER LM DEVITA VT LISTER TA ARMITAGE JO
Citation: W. Hiddemann et al., LYMPHOMA CLASSIFICATION - THE GAP BETWEEN BIOLOGY AND CLINICAL MANAGEMENT IS CLOSING, Blood, 88(11), 1996, pp. 4085-4089
SINGLE FRACTION HIGH-DOSE CHEMOTHERAPY WITH OR WITHOUT TOTAL-BODY IRRADIATION (TBI) AND AN AUTOLOGOUS BONE-MARROW TRANSPLANT (ABMT) FOR PATIENTS WITH RELAPSED REFRACTORY HODGKINS-DISEASE - HIGH SURVIVAL RATE IN CHEMORESISTANT DISEASE - A SOUTHWEST-ONCOLOGY-GROUP (SWOG) TRIAL/
Authors: STIFF PJ UNGER J FISHER RI MCCALL A NADEMANEE A BLUME K HORNING S FORMAN SJ
Citation: Pj. Stiff et al., SINGLE FRACTION HIGH-DOSE CHEMOTHERAPY WITH OR WITHOUT TOTAL-BODY IRRADIATION (TBI) AND AN AUTOLOGOUS BONE-MARROW TRANSPLANT (ABMT) FOR PATIENTS WITH RELAPSED REFRACTORY HODGKINS-DISEASE - HIGH SURVIVAL RATE IN CHEMORESISTANT DISEASE - A SOUTHWEST-ONCOLOGY-GROUP (SWOG) TRIAL/, Blood, 88(10), 1996, pp. 1930-1930
PROGNOSTIC IMPLICATIONS OF PLOIDY AND PROLIFERATIVE ACTIVITY IN THE DIFFUSE, AGGRESSIVE NON-HODGKINS-LYMPHOMAS
Authors: WINTER JN ANDERSEN J VARIAKOJIS D GORDON LI FISHER RI OKEN MM NEIMAN RS JIANG SW BAUER KD
Citation: Jn. Winter et al., PROGNOSTIC IMPLICATIONS OF PLOIDY AND PROLIFERATIVE ACTIVITY IN THE DIFFUSE, AGGRESSIVE NON-HODGKINS-LYMPHOMAS, Blood, 88(10), 1996, pp. 3919-3925
EVIDENCE FOR EOSINOPHIL ACTIVATION IN CANCER-PATIENTS RECEIVING RECOMBINANT INTERLEUKIN-4 - EFFECTS OF INTERLEUKIN-4 ALONE AND FOLLOWING INTERLEUKIN-2 ADMINISTRATION
Authors: SOSMAN JA BARTEMES K OFFORD KP KITA H FISHER SG KEFER C ELLIS TA FISHER RI HIGGINS TJ GERALD GJ
Citation: Ja. Sosman et al., EVIDENCE FOR EOSINOPHIL ACTIVATION IN CANCER-PATIENTS RECEIVING RECOMBINANT INTERLEUKIN-4 - EFFECTS OF INTERLEUKIN-4 ALONE AND FOLLOWING INTERLEUKIN-2 ADMINISTRATION, Clinical cancer research, 1(8), 1995, pp. 805-812
Risultati: 1-25 | 26-50 | 51-57